Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHRM 864 > Lecture 18 - Oncologic Emergencies > Flashcards

Lecture 18 - Oncologic Emergencies Flashcards

1
Q

Oncologic emergency

A

potentially morbid or life-threatening events directly or indirectly related to a patient’s tumor or its treament
can occur at any time during a malignancy, from the presenting sx to end-stage disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Examples of oncologic emergencies

A

metabolic, neurologic, cardiovascular, pulmonary, infectious

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Metabolic

A

hypercalcemia of malignancy (HCM)
tumor lysis syndrome (TLS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Neurologic

A

spinal cord compression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Cardiovascular

A

superior vena cava syndrome (SVC)
malignant pericardial effusion
cardiac tamponade

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Pulmonary

A

pleural effusions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Infectious

A

neutropenic fever

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tumor lysis syndrome (TLS)

A

constellation of metabolic derangements resulting from death of malignant cells - massive release of intracellular contents into bloodstream that overwhelms the body’s homeostasis
serious and life-threatening

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

TLS risk factors

A

tumor specific risk factors: high tumor burden, high tumor grade with rapid cell turnover, and treatment sensitive tumors
pt specific risk factors: age, preexisting renal impairment, concomitant use of drug known to increase uric acid (aspirin, alcohol, thiazide diuretics, caffeine)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

TLS pathophysiology

A

hyperkalemia, exacerbated by AKI
hyperuricemia - catabolism of nucleic acids, poor solubility in urine = uric acid crystal precipitation in renal tubules –> AKI
hyperphosphatemia - excess phosphate binds to calcium and crystalize –> deposits into tissues, exacerbates AKI
hypocalcemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Acute renal failure

A

48-72 hours after initiation of therapy
sx: oliguria, N/V, lethargy, fluid overload, edema, CHF, seizures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

TLS: principles of management

A

prevention and immediate management is key
management of acute TLS: identify high risk pts - proactively institute aggressive prophylactic strategies to prevent and/or reduce the severity of TLS; monitor electrolytes; aggressive hydration - enhances urine flow, promotes uric acid and phosphate excretion; control of hyperuricemia - with uric acid lowering drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Low risk prophylaxis

A

monitoring, hydration, +/- allopurinol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Intermediate risk prophylaxis

A

monitoring, hydration, allopurinol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

High risk prophylaxis

A

monitoring, hydration, rasburicase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Aggressive hydration

A

fluids and hydration: improves intravascular volume, renal perfusion, and glomerular filtration
decreases risk of life-threatening hyperkalemia
maintain urine output = 80-100 mL/m^2/hr
always consider cardiac function when assessing fluid rate and volume!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Hyperuricemia

A

uric acid + xanthine are both potentially nephrotoxic –> freely filtered at glomerulus; becomes overwhelmed = crystalizes within tubular lumen, causes direct tubular injury = AKI
humans lack a functional gene for urate oxidase –> further metabolizes uric acid to freely soluble and excretable allantoin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Allopurinol medical management

A

allopurinol is converted to oxypurinol which inhibits the conversion of xanthine to uric acid, decreases generation of uric acid
only prevents formation of new uric acid, does not facilitate breakdown of uric acid already produced
reduces risk of obstructive uropathy
renal adjustment for CrCl < 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Allopurinol limitations

A

doesn’t reduced already formed uric acid, may take several days to lower uric acid, decreases clearance of certain chemos - 6-MP, azathioprine, high-dose methotrexate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Rasburicase

A

recombinant urate oxidase that catalyzes the oxidation of uric acid into soluble metabolite, allantoin
decreases uric acid levels, including already formed uric acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Rasburicase limitations

A

if you have glucose-6-phosphate dehydrogenase deficiency, do not use rasburicase - risk of severe hemolysis reactions
contraindicated in women pregnant/breast-feeding
degrades uric acid within blood samples
very expensive

22
Q

TLS management of electrolyte abnormalities: hyperkalemia

A

eliminate all IV and oral potassium supplements
mild: can give IV fluids and loop diuretic PRN or sodium polystyrene sulfonate
severe: IV calcium gluconate or dextrose and regular insulin or sodium bicarb or IV fluids and loop diuretics

23
Q

TLS management of electrolyte abnormalities: hyperphosphatemia

A

minimize phosphate intake
oral phosphate binder for short term use
sevelamer

24
Q

TLS management of electrolyte abnormalities: hypocalcemia

A

do NOT treat if asymptomatic
symptomatic: IV calcium gluconate

25
Q

TLS monitoring

A

prior to initiation of certain chemo: uric acid, phosphorous, potassium, calcium, LDH, serum creatinine, urine output

26
Q

Malignant spinal cord compression (MSCC)

A

caused by compression of dural sac, spinal cord, or cauda equina by an extradural or intradural mass
hematogenous spread with bony metastasis to vertebral spine causes collapse and compression
early diagnosis and treatment are ESSENTIAL to prevent permament damage and possible paralysis

27
Q

What cancers cause MSCC?

A

all cancers can
most common: breast, lung, prostate

28
Q

MSCC sx

A

pain: most common 1st sx
motor deficit: limb weakness is 2nd most comon sx; unsteady gait, rapid onset/difficulty walking, standing, transferring from bed to chair
sensory deficit: paresthesia, decreased sensation and numbness of toes/fingers
autonomic dysfunction: bladder + bowel dysfunction: urinary retention, urinary or fecal incontinence or constipation

29
Q

MSCC pathophysiology

A

1st stage is development of compression in spinal column from tumor cells; destruction of corticol bone by tumor can compound this compression (vertebral-body collapse)
vasogenic edema because of spinal cord compression ischemia leads to white matter necrosis + gliosis –> caused by cytokines, inflammatory markers, and neurotransmitters

30
Q

MSCC diagnosis

A

MRI of WHOLE spine

31
Q

MSCC treatment

A

start steroids immediately! - dexamethasone: reduces edema, inhibits inflammatory responses, delays onset of neurological deficit
surgery + radiotherapy are the only treatments that leads to immediate relief of MSCC
bisphosphonates

32
Q

Radiotherapy

A

effective in prevention of further tumor growth and neurologic damage, especially in pts with radiosensitive tumors

33
Q

Surgery

A

indications: spinal instability, previous radiation, disease progression despite radiation, radioresistant tumor, paraplegia
laminectomy/anterior decompression
vertebroplasty
kyphoplasty

34
Q

Laminectomy/anterior decompression

A

some or all surgical removal of pathological vertebral body and tumor mass

35
Q

Vertebroplasty

A

bone cement injected into fractured bone

36
Q

Kyphoplasty

A

balloon inserted and inflated to expand the compressed vertebra to its normal height before filling the space with bone cement

37
Q

Bisphosphonates

A

should be offered in pts with vertebral involvement to reduce risk of vertebral fracture/collapse
also alters/reduces pain

38
Q

Superior vena cava syndrome

A

SVC: major blood vessel for venous blood flow from head, neck, upper extremities to heart and lungs to the heart
disease pressing on SVC, not getting adequate blood flow; thin-walled SVC gradually compressed by tumor outside vessel –> impaired venous drainage from head, neck, and upper extremities

39
Q

SVC syndrome occurs in setting of

A

an extrinsic compression or other occlusion of the superior vena cava

40
Q

SVC syndrome s/s

A

facial/arm edema, distention of superficial neck and chest wall veins, hypotension, dyspnea at rest, cough, stridor, dysphagia, HA, syncope, dizziness

41
Q

SVC syndrome treatment

A

if left untreated: hemodynamic compromise, airway compromise, increased intracranial pressure leading to cerebral edema, intracerebral bleeding
primary goal in SVC management = alleviation of sx and treatment of underlying disease
tumor-specific, stage-specific treatment plan

42
Q

SVC syndrome: adjunctive therapies

A

elevation of head to decrease hydrostatic pressure + edema
steroids - only in pts with steroid sensitive tumor and pts undergoing radiation therapy
diuretics to decrease arterial pressure

43
Q

Malignant pleural effusion (MPE)

A

complication of advanced malignancy
most common cancers: lung, breast, and lymphoma
pleural effusions: accumulation of fluid within pleural space (thin membranes that lines lungs and chest wall)

44
Q

Effusions form when

A

cancer cells spread to pleural space –> increases production and decreases absorption of pleural fluid

45
Q

MPE sx

A

no sx –> acute respiratory distress
dyspnea most common presenting sx; pleuritic chest pain

46
Q

MPE diagnosis

A

chest x-ray
ultrasound of chest immediately pre-procedure to identify appropriate sites for drainage

47
Q

MPE management

A

thoracentesis
pleural fluid analysis

48
Q

Thoracentesis

A

needle aspiration of fluid from pleural effusion
risk: pneumothorax, puncture of intra-abdominal organ, re-expansion pulmonary edema, chest discomfort

49
Q

Pleural fluid analysis

A

fluid sent for total protein, LDH, cell count, cell differential, gram stain, aerobic/anaerobic bacterial cultures
fluid examination: gram stain, acid-fast stain, total cell counts, LDH, glucose, protein, pH
classified as transudate or exudate

50
Q

Thoracentesis indication

A

minimize acute sx temporarily
used in pts with life expectancy < 1-3 mo
risks: re-expansion pulmonary edema, pleural adhesions, infection, hypotension

51
Q

Pleurodesis indication

A

activates inflammatory cascade leading to adhesion of pleural layers
useful for pts with life expectancy > 1-3 mo
administered through chest catheter or through video-assisted thorascopic surgery
agents: talc, doxycyline, bleomycin
risks: pleuritic chest pain, fever, systemic inflammation

52
Q

Pleural catheters and pleurectomy

A

pleural catheter indication: indwelling pleural catheter drained frequently
risks: infection, tumor seeding of catheter
pleurectomy indication: partial or radical removal of pleura, beneficial for pts with prolonged life expectancy or pts with uncontrolled pleural effusions

PHRM 864 (20 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions